MRSA Drugs Market Growth, Trends and Value Chain 2020-2027

 The Global MRSA Drugs Market is expected to register a CAGR of 4.4% to reach USD 4,312.2 million till 2023. Methicillin-resistant staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of the pathogen. This infection is generally associated with invasive procedures such as surgeries, intravenous tubing, and sometimes through the skin to skin contact. MRSA drugs are used to kill or restrain methicillin-resistant staphylococcus aureus infection.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/2102

The increase in the prevalence of MRSA infections and number of hospitals, growing awareness about a bacterial infection, and increase in immuno-compromised population are expected to enhance the market growth. However, the high cost of novel MRSA drugs and hospital readmissions reduction program is projected to curb the growth of the market.

Market Dynamics

MRSA drugs have been gaining significant growth in recent years owing to the rising awareness about MRSA infections. For instance, October is celebrated as world MRSA awareness month and November 18, is celebrated as antibiotic awareness day in Europe to raise awareness of antibiotic resistance and promote the judicious use of antibiotics. Thus, the growing awareness about the cause and treatment related to bacterial infection among the population led to an increased usage of MRSA drug market, which thereby provides a favorable scenario for the market to grow during the forecast period.

Segmentation

The global MRSA drugs market, by drug class, has been segmented into sulfa drugs, tetracyclines, oxazolidinones, folate antagonists, lipopeptide, glycopeptide antibiotics, and others. Based on MRSA types, the MRSA drugs market has been categorized as hospital-acquired (HA-MRSA) and community-acquired (CA-MRSA). By disease indication, the market is divided into skin infections, bone and joint infections, and bacteremia, and animal infections. Based on end user, the MRSA Drugs market has been categorized as hospitals and clinics, research and academic institutes, and others.

Regional Analysis

The global MRSA drugs market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is expected to hold the largest share of the global MRSA drugs market. This is owing to the presence of key market players, well-developed healthcare infrastructure, in the US and Canada. Canada held 25% in North America MRSA Drugs market in 2016.

Europe holds the second position in global MRSA drugs market due to the increasing research & development in the healthcare industry, availability of funds for research, rising cases of bacterial infection, and increasing adoption of novel drugs for the treatment of MRSA.

Asia-Pacific is projected to be the fastest-growing region in the global market due to the rapidly developing medical industry, the presence of a huge patient pool, and increasing expenditure in healthcare by the government. China held a share of 25.1% in the Asia-Pacific MRSA drugs market in 2016. The Middle East & Africa holds the least market share in the global MRSA drugs market.

Key Players

The prominent players in the global MRSA drugs market are Merck KGaA (UK), Olon (Italy), Allergan (Dublin, Ireland), Baxter (US), Theravance Biopharma (Theravance Biopharma), Pfizer (US), Mylan NV (US), and Novartis (Switzerland).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/mrsa-drugs-market-2102

Mastitis Market to Witness Widespread Expansion During 2020-2027

 The Global Mastitis Market is expected to register a CAGR of 15.07% to reach USD 18,338.80 Million till 2023. Mastitis is an infection in the tissue of one or both mammary glands inside the breast. It usually affects women who are breastfeeding, and it results from a blocked or a plugged duct. In bovine, mastitis is the inflammation of the mammary gland and udder tissue due to bacterial invasion of the teat canal by a variety of bacterial sources present on the farm, and can also occur as a result of chemical, mechanical, or thermal injury to the cow’s udder.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5379

The rising cases of breast cancer, increasing rate of pregnancy, and unhygienic barn conditions causing contagious mastitis in bovines across the globe is expected to enhance the market growth. However, the lack of awareness and complications in diagnosis due to similar symptoms of breast cancer & mastitis are projected to curb the growth of the market.

Market Dynamics

Mastitis has been gaining significance in recent years, owing to the rising incidence of breast cancer. For instance, the Breast Cancer Research Foundation estimated that 266,120 new cases of invasive breast cancer were diagnosed in women in 2018 in the US. Similarly, the UK witnessed around 11,563 deaths due to breast cancer in 2016, according to the Cancer Research UK. Whereas, according to the World Cancer Research Fund International, Belgium had the highest rate of breast cancer in women in 2017. Such a vast population suffering from breast cancer boosts market growth during the forecast period.

Segmentation

The global mastitis market, by type, has been segmented into bovine and human. Based on treatment, the Mastitis market has been categorized as bovine and human. Based on end user, the mastitis market has been classified as veterinary centers and hospital & clinics.

Regional Analysis

The global mastitis market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is expected to hold the largest share of the global mastitis market. North America is expected to dominate the market, mainly due to the increasing p prevalence of mastitis among the bovine population and increasing incidence of breast cancer in the region.

Europe is expected to account for the second-largest market share during the forecast period. The factors responsible for market growth in this region are advanced treatment facilities, rising government initiatives to promote healthy breastfeeding, and growing healthcare expenditure. For instance, according to Eurostat, Germany spent over EUR 321 billion in 2014.

Asia-Pacific is estimated to be the fastest-growing region in the global market due to the presence of rapidly developing economies such as China, India, and South Korea. Moreover, the vast patient pool of chronic diseases and government initiatives of healthcare reforms will support the growth of the market.

The mastitis market in the Middle East & Africa is expected to grow due to the affordability and accessibility of healthcare.

Key Players

The prominent players in the global Mastitis market are Bayer AG (Germany), Oncothyreon Inc (US), OncoGenex (US), Apthera Inc. (UK), Zoetis Inc. (US), Boehringer Ingelheim GmbH (Germany), Merck Co. & Inc. (US), Astellas Pharma Inc. (Japan), Pfizer Inc. (US), Novartis AG (Switzerland), Sanofi SA (France), and F. Hoffmann-La Roche AG (Switzerland).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/mastitis-market-5379

Global Egg Allergy Market size and forecast, 2020-2027

 The Global Egg Allergy Market is expected to register a CAGR of 7.10%and is anticipated to reach USD 2304.3 Million by 2023. Egg allergies are the most common food allergies. Symptoms of egg allergy can occur immediately or within a few minutes or a few hours. Egg allergy can affect infants as well as adults. The adverse effects of egg allergy can vary from hives or rashes to a severe allergic reaction known as anaphylaxis. Egg allergy happens when there is an overreaction to eggs by the immune system. The immune system identifies egg proteins as harmful and triggers an allergic reaction.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4734

The increasing prevalence of egg allergy and improved allergy diagnosis are the major drivers propelling market growath. However, the lack of awareness in developing countries and high cost constrain the growth of the market.

Market Dynamics

The continued growth in several egg allergy patients is responsible for the increasing demand for required diagnostic tests and medication such as epinephrine autoinjectors, and ultimately, it is propelling the growth of the market. For instance, according to the report published by, McGill University in 2016, egg allergy is common in infants and young children and affects 1 to 2% of the preschool children. Additionally, improved allergy diagnosis is likely to support market growth. On the other hand, the lack of awareness in developing countries and high cost is anticipated to hamper the market growth.

Segmentation

The global egg allergy market has been segmented into age type, diagnosis & treatment, and end user. By age type, the market has been segmented into children and adults. The global egg allergy market has two primary sides—diagnosis & treatment. The global egg allergy market, by diagnosis, has been segmented into skin test, blood test, food challenge, and others. The global egg allergy market, by treatment, has been segmented into medication and oral immunotherapy. By end-user, the market has been segmented into hospitals and clinics, diagnostic centers, research institutes, and others. The hospitals and clinics segment accounted for a market value of USD 729.2 million in 2017.  

Key Players

The prominent players in the global egg allergy market are Sanofi SA (France), Genentech, Inc. (the US), Quest Diagnostics (US), ImmuneTech (US), HYCOR Biomedical (US), Kaleo, Inc. (the US), Alletess Medical Laboratory (US), Creative Diagnostics (US), Imutest Ltd (UK), Mylan NV (US), and Impax Laboratories (US).

Some of the key strategies followed by the players operating in the global egg allergy market were innovation, product development, acquisition, and expansion.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/egg-allergy-market-4734

Soaring Demand Drives Global Tissue Microarray Market Growth During the Forecast Period, 2020-2027

 The Global Tissue Microarray Market is expected to register a CAGR of 10.54% and is anticipated to reach USD 10,914.54 million by 2023. Tissue microarrays are paraffin blocks that are created by separating cylindrical tissue cores from different paraffin donor blocks and re-embedding these into a microarray at defined array coordinates. With the help of tissue microarray, up to at least 1000 tissue samples can be arrayed into a single paraffin piece. It allows simultaneous analysis of molecules present in DNA, mRNA, and protein levels under identical, standardized conditions on a single glass slide. This adaptable strategy, in which data analysis is automated, facilitates retrospective and prospective human tissue studies.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1213

The increasing application in drug discovery, increasing prevalence of cancer, growing advancements in biotechnology and pharmaceutical companies, and rising demand for cost-effective and accurate diagnostic methods are the major drivers propelling market growth. However, tissue microarray may not be fruitful for heterogeneous cancers, which is likely to constrain the growth of the market.

Market Dynamics

The prevalence of cancer is one of the crucial factors that drive the growth of the tissue microarray market. According to the American Cancer Society, in 2017, nearly 13% of all cancers diagnosed in adults aged 20. It further stated that rates of liver cancer, thyroid cancer, and melanoma are increasing from last few years. According to US Breast Cancer Statistics, about 1 in 8 US women (about 12%) will develop invasive breast cancer throughout their lifetime. In 2017, an estimated 252,710 new cases of invasive breast cancer were expected to be diagnosed in women in the US, along with 63,410 new cases of non-invasive (in-situ) breast cancer.

Moreover, increasing advancements in biotechnology and pharmaceutical companies and growing demand for cost-effective and accurate diagnostic methods have fueled the growth of the market. On the other hand, tissue microarray is that it may not be fruitful for heterogeneous cancers anticipated to hamper the market growth.

Segmentation

The global tissue microarray market has been divided into the procedure, technology, application, and end user. By procedure, the market has been segregated into immunohistochemistry, fluorescent in-situ hybridization, and frozen tissue array. Based on technology, the market has been segmented into DNA microarray, polymerase chain reaction (PCR), next-generation sequencing, northern blotting, and western blotting. Based on the application, the market has been bifurcated into oncology, gene expression profiling, SNP detection, double-stranded B-DNA microarrays, comparative genomic hybridization, and sequencing bioinformatics. By end-user, the market has been classified as pharmaceutical and biotechnological companies and research organization. The research organization segment accounted for a market value of USD 1876.02 million in 2016.

Key Players

The prominent players in the global tissue microarray market are Agilent Technologies, Illumina, Inc., Protein Biotechnologies Inc., Asterand Bioscience, Pantomics Inc., Applied Microarrays, Arrayit, Phalanx Biotech, QIAGEN, Takara Bio, Perkin Elmer, and Merck Sharp & Dohme Corp.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/tissue-microarray-market-1213

Automated Hospital Beds Market to Witness Widespread Expansion During 2020-2027

 The Global Automated Hospital Beds Market is expected to register a CAGR of 5.97% and is anticipated to reach USD 2,553.4 million by 2023. 

Automated hospital beds are specially designed for hospitalized patients in need of some form of health care services. These hospitals beds have special features both for the comfort and well-being of the patient and for the convenience of health care workers. Most common features of automated hospital beds are automated adjustable height for the entire bed including the head and the feet, adjustable side rails, and electronic buttons to operate both the bed and other nearby electronic devices.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4250

The increase in the number of various acute and chronic disorders, rising geriatric population, increased number of obese people, continuous development in the designs of the hospital beds for the betterment and more comfort of the patients, and rising healthcare expenditure are the major drivers propelling market growth. However, the high cost of automated hospital beds and expensive maintenance of automated hospital beds are hampering the growth of the market.

Market Dynamics

The rise in the incidence rates of chronic disorders is expected to drive the growth of the market. According to the American Autoimmune Related Diseases Association, in 2017, approximately 50 million Americans were suffering from autoimmune diseases, and more than USD 591 million was spent on research and development of autoimmune disorders. Moreover, the increasing geriatric population, increased number of obese people are also likely to support market growth. On the other hand, the high cost of automated beds and the expensive maintenance of hospital beds is anticipated to hamper the market growth.

Segmentation

The global automated hospital beds market has been segmented into type, technology, type of treatment, usage and end user. By type, the market has been segmented into semi-automatic hospital beds and fully automatic hospital beds. Technology segment has been divided into basic automated hospital beds and smart, automated hospital beds. Based on the type of treatment, the market has been segmented into critical care, acute care, and long-term care. Based on usage, the market has been segmented into general-purpose, intensive care, delivery/birthing, bariatric, pediatric, psychiatric care, pressure relief, and others. By end-user, the market has been segmented hospitals & clinics reproductive care centers, dentistry, home care, and others. The hospitals & clinics segment accounted for a market value of USD  627.4 million in 2016.

Key Players

The prominent players in the global automated hospital beds market are ArjoHuntleigh, Gendron Inc, Hill-Rom Holdings, Invacare Corporation, Linet spol. SRO, Medline Industries, Inc., Stryker Corporation, Paramount Bed Holdings Co., Ltd., and Others.

Regional Analysis

The global automated hospital beds market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.

The European region is estimated to dominate the global automated hospital beds market during the forecast period. This is attributed to the continuous innovation and new product development, moreover, to rise in prevalence of life-threatening diseases, increasing healthcare expenditure and increasing technological advances play a vital role in the growth of the regional market. Furthermore, in an automated hospital beds market, Europe accounted for a market share of 36.0% in 2016. The North America market for automated hospital beds is expected to be the second-largest during the forecast period. Factors such as stable economic conditions and continuously developing technologies and significant investments by hospitals to upgrade their equipment’s including beds is expected to boost the growth of the market in this region. For instance, According to WHO, the North American population is projected to grow by 42% from 2000 to 2050, and so it is imperative that the supply of health care maintains pace with the increased demand

Additionally, the companies operating in the market are mainly concentrating on strategic collaborations and mergers and acquisition, which is expected to support market growth. Asia-Pacific is estimated to be the fastest-growing market due to the increasing incidence of chronic diseases, the government encouragement in the healthcare sector, and growing the working population in the healthcare industry. Furthermore, the market in the Middle East & Africa is expected to witness steady growth due to limited access to healthcare facilities.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/automated-hospital-beds-market-4250

Impact of Existing and Emerging Global Companion Diagnostics for Oncology Market Trends And Forecast 2020-2027

 Market Overview

Global Companion Diagnostics for Oncology Market was valued at USD 1,603.16 Million in 2019 and is expected to register a CAGR of 22.57% during the forecast period of 2020 to 2027.

Companion diagnostic (CDx) is a diagnostic testing kit majorly used by pharmaceutical companies for the development of personalized medicine. CDx tests provide information about the effective use of a corresponding therapeutic product by analyzing the genetic material. With the rise in cancer prevalence, coupled with increasing strategic initiatives, there has been a huge demand for companion diagnostics in the oncology area. The growing prevalence of cancer across the globe is increasing the preference for targeted therapy, which is affecting the demand for CDx tests. According to Cancer Research UK, there were 17 million new cases of cancer across the world in 2018, in which lung and breast cancer accounted for the largest share, followed by colorectal and prostate cancer.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/10422 

Market Dynamics

The key factors driving the market growth are increasing R&D and drug-diagnostic co-development, growing preference for personalized medicine, increasing global incidence of cancer, and increasing product approvals by major players. However, the lack of reimbursement in developing regions may hamper the market growth. The entry of market players in evolving economies creates an opportunity to drive the companion diagnostics for oncology market.

Major market players are focusing on various growth strategies such as product launches, product advancements, and business expansions to cater to the growing need for personalized medicine. These product launches and business expansion drive the growth of the companion diagnostics for oncology market. For instance, in March 2020, Thermo Fisher signed a strategic agreement with Janssen Services to co-develop a companion diagnostic product related to oncology, which will support clinical trial enrollment globally. In March 2019, Roche launched the Ventana PD-L1 (SP142) Assay in Europe as the first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq. Similarly, in March 2019, Roche received the US FDA approval for its Ventana PD-L1 (SP142) assay approved as the first companion diagnostic to identify triple-negative breast cancer patients eligible for the treatment with Tecentriq in combination with Abraxane. Furthermore, in April 2018, Illumina entered a collaboration with Bristol Myers Squibb Company to utilize Illumina’s next-generation sequencing technology to develop and globally commercialize companion diagnostics for Bristol-Myers Squibb Company’s oncology immunotherapies, and the growing prevalence of cancer across the globe is increasing the preference for targeted therapy which is affecting the demand for CDx tests.

Segmentation

Global Companion Diagnostics for Oncology Market has been divided based on Products & Services, Technology, Indication, and End User.

Global Companion Diagnostics for Oncology Market, on the basis of product & service, has been segmented into assays, kits & reagents and software & services. The assays, kits, & reagents segment is expected to be the largest of 62.1% in 2019 and is projected to be the fastest market owing to their continuous requirement by end users.

Based on technology, the global companion diagnostics for oncology market is segmented into polymerase chain reaction (PCR) and next-generation sequencing (NGS). By technology, polymerase chain reaction (PCR) held a larger market share of 53.8% in 2019, whereas the NGS segment accounted for a CAGR of 25.05% during the forecast period of 2020 to 2027.

The global companion diagnostics for oncology market, on the basis of indication, has been segmented into breast cancer, lung cancer, colorectal cancer, gastric cancer, melanoma, and others. The breast cancer segment accounted for the largest market share in 2019, owing to the huge population suffering from cancer across the globe.

The global companion diagnostics for oncology market, on the basis of end user, is segmented into pharmaceutical & biopharmaceutical companies, laboratories, contract research organizations, and others. The pharmaceutical & biopharmaceutical companies segment accounted for the largest share of 38.2% in 2019, owing to the rising adoption of companion diagnostics for oncology techniques among researchers and clinicians.

Regional Analysis

Global Companion Diagnostics for Oncology Market based on region is segmented into four main regions, including the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas accounted for the major share in 2019, whereas Asia-Pacific is projected to be the fastest-growing region during the forecast period.

In the global companion diagnostics for oncology market, the Americas held the largest share of 37.3% in 2019. The market growth in the Americas is due to the high prevalence rate of cancer and other chronic disorders and rising healthcare expenditure. According, to the National Institutes of Health, it was estimated that 1,735,350 new cases of cancer were diagnosed in the US in 2018. Additionally, the American Cancer Society estimated that 1.8 million new cancer cases would be diagnosed in 2020 in the US.

Europe acquired the second-largest market share in 2019. The market is expected to register a sturdy growth rate during the forecast period due to the presence of a large number of companies, growing research and development activities to develop targeted drug therapy for a cancer patient, and rising per capita income increases the preference for personalized medicine. According to the European Journal of Cancer, there were around 3.9 million new cases and 1.9 million deaths from cancer in Europe in 2018. The increasing cancer population supports market growth in this region.

Asia-Pacific is anticipated to be the fastest-growing regional market during the forecast period. The rapid growth of the Asia-Pacific regional market is due to the rising number of cancer patients and the growing presence of market players. According to the Global Cancer Observatory, around 1,157,294 cases of cancer were reported in India in 2018. Additionally, growing research funding, rising investments by pharmaceutical and biotechnology companies and growing awareness about personalized therapeutics in several APAC countries are expected to drive the growth of the Asia-Pacific market.

The Middle East & Africa accounted for the least value of USD 82.64 million in 2019. The companion diagnostics for oncology market in countries such as Kuwait, the UAE, and Saudi Arabia are likely to show steady growth due to increasing cancer cases, rising drug discovery, and increasing preference for personalized medicines. Also, the growing number of hospitals and research laboratories and increasing investment by healthcare companies in this region drives the growth of the market in Middle East & Africa.

Key Players

The Prominent Players in the Global Companion Diagnostics for Oncology Market are Agilent Technologies Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, BioMérieux SA, Foundation Medicine, Archer Dx, Qiagen, Thermo Fisher Scientific Inc., Amoy Dx, and Abbott.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/companion-diagnostics-oncology-market-10422 

Surgical Instrument Tracking System Market – Insights on Upcoming Trends 2027

 Global Surgical Instrument Tracking System Market was valued at USD 186.85 Million in 2019 and is expected to register a CAGR of 15.07% during the forecast period of 2020 to 2027.

Surgical instrument tracking systems are systems that can combine scanning technology and application software. They help healthcare professionals to access time-saving tools, leading to them performing efficient and time-saving procedures. The surgical tracking systems are very much useful in organizing surgical sets, usage cycle tracking, and documentation of instruments used, understanding the replacement of instruments, and other applications.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1391 

Factors that drive the market growth are the high rate of adoption of the surgical instrument tracking systems by hospitals, the need to meet unique device identification mandates, the convenience provided by surgical instrument tracking system in the management of inventories, and the increasing number of surgical instruments used in various surgeries. However, the high cost of implementing automated tracking systems coupled with a fall in the number of surgeries due to a pandemic is hampering the growth of the market.

Previously, it was only used for instrument count sheet management along with a few basic tasks such as traceability of instruments. The 2D barcodes have helped sterile handling and identification of instruments and help in tracking the history of each instrument’s use. Major healthcare providers are signing long-term agreements with surgical instrument tracking system suppliers for improving the quality of the inventory management systems. For instance, recently, Universal Health Services, Inc., one of the hospital management companies, which have a large network of hospitals in the US, signed a multi-year contract with Censis Technologies, Inc. for its surgical instrument tracking system Censitrac.

Market Dynamics

The surgical instrument tracking systems are used in the healthcare facilities to streamline the workflow, regulate the costs, and reduce waste as well as for effective inventory management. There are several benefits of surgical instrument tracking systems. Key players operating in the surgical instrument tracking system market are engaged in the acquisition of companies with similar products to expand their product portfolio and maintain a global footprint. For instance, in October 2019, Fortive Corporation (US) acquired Censis Technologies, Inc. (US). This acquisition helped Fortive Corporation to add a surgical instrument tracking systems product portfolio.

The growth of the global surgical instrument tracking system market can be attributed to the high rate of adoption of the surgical instrument tracking systems by hospitals, technological advancements in the surgical instrument tracking system market, and the growing number of surgical procedures globally. Technological advancements in the surgical instrument tracking system segment are reducing the time required for the process and increasing the accessibility and efficiency of inventory management in the medical facilities. It is also providing real-time data collection and monitoring of surgical instruments used in the healthcare facility. The market players have been engaged in the development of innovative products and services for catering to the needs of the healthcare providers. For instance, in October 2018, Spa Track launched a new Auto-Scanner RFID Surgical Instrument. It is a hetero-directional, rotating processing system that takes only 12 seconds for screening a complete instrument plate and can be inaccurate monitoring of every single registration number of items. Such technological advancements are expected to encourage the growth of the global surgical instrument tracking system market during the forecast period

Segmentation

Global Surgical Instrument Tracking System Market has been divided based on Components, Technology, and End-Use.

The market, based on components, has been segmented into hardware, software, and services. The hardware segment accounted for a significant market share of 51.6% in 2019. This large share can be attributed to its growing technological advancements, which is driving the adoption of these devices for inventory management. The hardware segment is further divided into readers, tags, and others.

The market, based on technology, has been bifurcated into barcode tracking and radio frequency identification. The Barcode tracking segment dominated the global surgical instrument tracking system market in 2019. Owing to the low cost of installation has resulted in the increased adoption of barcode technology in the surgical instrument tracking systems market. It held a market share of 86.9% in 2019.

On the basis of end use, the global surgical instrument tracking system market has been classified as hospitals and others. The hospitals segment dominated the global surgical instrument tracking system market in 2019. The large share of 83.0% of hospitals is attributable to the need to cut healthcare expenditure and manage existing instruments for tracking solutions.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/surgical-instrument-tracking-system-market-1391